Preclinical News and Research

RSS

Mouse study provides new way to test novel therapies for liver infections

How do you study-and try to cure in the laboratory-an infection that only humans can get? A team led by Salk Institute researchers does it by generating a mouse with an almost completely human liver.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

24 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

TCAD therapy active and synergistic against drug resistant influenza virus strains

Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

23 Feb 2010

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

23 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.

22 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Research shows natural compound in marine sponges reduces cancer cell motility

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research) led by Kristiina Vuori, M.D., Ph.D., have discovered that the natural compound sceptrin, which is found in marine sponges, reduces cancer cell motility (movement) and has very low toxicity.

19 Feb 2010

Unusual compounds in pitcher plant could prove effective against human fungal infections

The moment insects like flies, ants and beetles fall into a pitcher, the plant's enzymes are activated and begin dissolving their new meal, obtaining nutrients such as carbon and nitrogen which are difficult to extract from certain soils.

19 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Johns Hopkins Medicine acquires Naviscan Positron Emission Mammography for radiotracer research

Johns Hopkins Medicine has become the latest academic medical center to acquire the Naviscan Positron Emission Mammography (PEM) scanner. The device will be utilized by Richard Wahl, M.D., F.A.C.R, Professor of Radiology and Nuclear Medicine at the Johns Hopkins University School of Medicine, in pre-clinical and translational research for the development of novel radiotracers.

18 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

AMRI announces Excelsyn acquisition

AMRI today announced the acquisition of Excelsyn Ltd., a well recognized leader in providing chemical development and manufacturing services to the pharmaceutical industry in Europe. Located in Holywell, North Wales, UK, Excelsyn has 60 employees and generated revenue of $15 million in 2009.

18 Feb 2010

Rondaxe and TD2 announce cancer drug development alliance

TGen Drug Development (TD2) and Rondaxe Enterprises today announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.

18 Feb 2010

Preclinical News and Research

Mouse study provides new way to test novel therapies for liver infections

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

Findings suggest bitter melon extract may help in preventing breast cancer

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

TCAD therapy active and synergistic against drug resistant influenza virus strains

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Research shows natural compound in marine sponges reduces cancer cell motility

Unusual compounds in pitcher plant could prove effective against human fungal infections

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Johns Hopkins Medicine acquires Naviscan Positron Emission Mammography for radiotracer research

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

AMRI announces Excelsyn acquisition

Rondaxe and TD2 announce cancer drug development alliance

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics